{"denoms":[{"counts":[{"groupId":"BG000","value":"444"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"666"}],"units":"Participants"}],"groups":[{"description":"Participants received letrozole 2.5 milligram (mg) orally QD (once daily) combined with palbociclib 125 mg QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"BG000","title":"Palbociclib Plus Letrozole"},{"description":"Participants received letrozole 2.5 mg orally QD combined with placebo QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"BG001","title":"Placebo Plus Letrozole"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.6","value":"61.7"},{"groupId":"BG001","spread":"11.2","value":"60.6"},{"groupId":"BG002","spread":"10.8","value":"61.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"444"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"666"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized."}